IL5 and asthma: Future studies should therefore test if the combination of the two ‘biomarkers’, namely a low β2-agonist reversibility together with a high peripheral blood eosinophilia, might be a better predictor of response to anti-IL-5 therapy than either parameter alone or other markers such as fractioned exhaled nitric oxide currently used to predict treatment responses in asthma.